Drug Trial Radar · NCT03596866
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Apr 19, 2019
Primary completion
Feb 27, 2024
Study completion Sep 18, 2024
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: * Brigatinib tablets * Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.
Conditions
- ALK+ Advanced NSCLC
Interventions
BrigatinibDrug
Brigatinib Tablets.
AlectinibDrug
Alectinib Capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1Time frame: Up to 33.8 months
Locations
114 sites in 20 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope and Innovation
Whittier, California
University Cancer and Blood Center
Athens, Georgia
New York Oncology Hematology - Albany Medical Center
Albany, New York
Virginia Cancer Specialists
Fairfax, Virginia
Sanatorio Duarte Quiros
Córdoba, Argentina
Centro Oncologico Riojano Integral
La Rioja, Argentina
Centro Para la Atencion Integral del Paciente Oncologico
San Miguel de Tucumán, Tucumán Province, Argentina
Klinikum Klagenfurt Am Worthersee
Klagenfurt, Carinthia, Austria
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Toronto University Health Network
Toronto, Ontario, Canada
Centro de Investigacion Clinica Bradford Hill
Recoleta, Santiago Metropolitan, Chile
Beijing Chest Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital - East
Beijing, Beijing Municipality, China
Peking University Cancer Hospital/Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The 307th Hospital of Chinese Peoples Liberation Army
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Affiliated Tumor Hospital of Harbin Medical University - The 3rd Affiliated Hospital of HMU
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Jilin Provincial Cancer Hospital (Changchun Cancer Hospital)
Changchun, Jilin, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Chang Gung Memorial Hospital Linkou Branch
Tianjin, Tianjin Municipality, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, China
General Hospital Pula
Pula, Croatia
Klinicki bolnicki centar Sestre milosrdnice
Zagreb, Croatia
Klinika za Pulmologiju
Zagreb, Croatia
Fudan University Shanghai Cancer Center
Dubrovnik, Dubrovnik-Neretva County, Croatia
Opca bolnica Dubrovnik
Dubrovnik, Dubrovnik-Neretva County, Croatia
Hopital Haut-Leveque
Pessac, Aquitaine, France
Hopital Albert Michallon
Grenoble, Auvergne-Rhône-Alpes, France
Centre Hospitalier Intercommunal de Creteil
Créteil, Île-de-France Region, France
Fudan University Shanghai Cancer Center
Créteil, Île-de-France Region, France
Hopital Foch
Suresnes, Île-de-France Region, France
Gustave Roussy
Villejuif, Île-de-France Region, France
Centre Hospitalier Universitaire de Toulouse- Hopital Larrey
Toulouse, Midi-pyrenees, France
Centre Hospitalier Le Mans
Le Mans, Pays de la Loire Region, France
Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer
Toulon, Provence-Alpes-Côte d'Azur Region, France
Thoraxklinik Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.